{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:20:17Z","timestamp":1794932417254,"version":"4.9.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.xcrm.2026.103094","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:50:46Z","timestamp":1791471046000},"page":"103094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipid-engineered antibody-based therapeutics target inflamed joints and lymph nodes to enhance rheumatoid arthritis treatment"],"prefix":"10.1016","volume":"7","author":[{"given":"Lei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichen","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6545-7867","authenticated-orcid":false,"given":"Yiran","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.103094_bib1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41584-022-00793-5","article-title":"Mechanisms of joint destruction in rheumatoid arthritis-immune cell-fibroblast-bone interactions","volume":"18","author":"Komatsu","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.xcrm.2026.103094_bib2","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.103094_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.xcrm.2026.103094_bib4","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial","volume":"144","author":"Kremer","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.xcrm.2026.103094_bib5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1056\/NEJMoa2201302","article-title":"Olokizumab versus placebo or adalimumab in rheumatoid arthritis","volume":"387","author":"Smolen","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103094_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.xcrm.2026.103094_bib7","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrrheum.2015.8","article-title":"Rheumatoid arthritis therapy reappraisal: Strategies, opportunities and challenges","volume":"11","author":"Smolen","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.xcrm.2026.103094_bib8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41584-023-01036-x","article-title":"25 years of biologic DMARDs in rheumatology","volume":"19","author":"Feldmann","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.xcrm.2026.103094_bib9","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41584-023-01043-y","article-title":"Are TNF inhibitors still the agent of choice for RA?","volume":"19","author":"Taylor","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.xcrm.2026.103094_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq4419","article-title":"Additive efficacy of a bispecific anti-TNF\/IL-6 nanobody compound in translational models of rheumatoid arthritis","volume":"15","author":"Biesemann","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.103094_bib11","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103094_bib12","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41584-021-00665-4","article-title":"Importance of lymphocyte-stromal cell interactions in autoimmune and inflammatory rheumatic diseases","volume":"17","author":"Noack","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.xcrm.2026.103094_bib13","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/s41467-025-57361-0","article-title":"Single cell immunoprofile of synovial fluid in rheumatoid arthritis with TNF\/JAK inhibitor treatment","volume":"16","author":"Xia","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103094_bib14","doi-asserted-by":"crossref","first-page":"14368","DOI":"10.1073\/pnas.182549099","article-title":"Despite ubiquitous autoantigen expression, arthritogenic autoantibody response initiates in the local lymph node","volume":"99","author":"Mandik-Nayak","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.xcrm.2026.103094_bib15","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.4049\/jimmunol.0903489","article-title":"Expanded CD23(+)\/CD21(hi) B cells in inflamed lymph nodes are associated with the onset of inflammatory-erosive arthritis in TNF-transgenic mice and are targets of anti-CD20 therapy","volume":"184","author":"Li","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2026.103094_bib16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41590-020-00816-x","article-title":"The immunology of rheumatoid arthritis","volume":"22","author":"Weyand","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2026.103094_bib17","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nrrheum.2017.205","article-title":"Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis","volume":"14","author":"Bouta","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.xcrm.2026.103094_bib18","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/hon.2525","article-title":"Rheumatoid arthritis and lymphoma: Incidence, pathogenesis, biology, and outcome","volume":"36","author":"Klein","year":"2018","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.103094_bib19","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1166\/jbn.2020.2966","article-title":"Engineered high-loaded mixed-monoclonal antibodies (adalimumab, rituximab and trastuzumab) polymeric nanoparticle for rheumatoid arthritis treatment: A proof of concept","volume":"16","author":"He","year":"2020","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.xcrm.2026.103094_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202305563","article-title":"Tannic acid-based nanomaterials for tolerogenic immunotherapy of rheumatoid arthritis","volume":"33","author":"Wu","year":"2023","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.xcrm.2026.103094_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202302575","article-title":"Targeting lymph nodes for systemic immunosuppression using cell-free-dNA-scavenging and cGAS-inhibiting nanomedicine-in-hydrogel for rheumatoid arthritis immunotherapy","volume":"10","author":"Cheng","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.xcrm.2026.103094_bib22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jconrel.2024.06.027","article-title":"Injectable butyrate-prodrug micelles induce long-acting immune modulation and prevent autoimmune arthritis in mice","volume":"372","author":"Cao","year":"2024","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.xcrm.2026.103094_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41573-022-00529-w","article-title":"Derivatization with fatty acids in peptide and protein drug discovery","volume":"22","author":"Kurtzhals","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.103094_bib24","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/s41551-020-0563-4","article-title":"Pharmacokinetic tuning of protein-antigen fusions enhances the immunogenicity of T-cell vaccines","volume":"4","author":"Mehta","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.xcrm.2026.103094_bib25","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/art.41585","article-title":"Suppression of rheumatoid arthritis by enhanced lymph node trafficking of engineered interleukin-10 in murine models","volume":"73","author":"Yuba","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.xcrm.2026.103094_bib26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature12978","article-title":"Structure-based programming of lymph-node targeting in molecular vaccines","volume":"507","author":"Liu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.103094_bib27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1126\/science.aav8692","article-title":"Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor","volume":"365","author":"Ma","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.103094_bib28","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/s41551-025-01400-0","article-title":"Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody-STING agonist conjugates","volume":"9","author":"Kimmel","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.xcrm.2026.103094_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23152-6","article-title":"A novel anti-TNF-alpha drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis","volume":"12","author":"Oyama","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2026.103094_bib30","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1021\/acsnano.9b01710","article-title":"Secreted protein acidic and rich in cysteine mediated biomimetic delivery of methotrexate by albumin-based nanomedicines for rheumatoid arthritis therapy","volume":"13","author":"Liu","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.xcrm.2026.103094_bib31","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/14712598.2023.2231344","article-title":"Ozoralizumab: First nanobody\u00ae therapeutic for rheumatoid arthritis","volume":"23","author":"Tanaka","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.xcrm.2026.103094_bib32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/antib4030141","article-title":"Pre-clinical intravenous serum pharmacokinetics of albumin binding and non-half-life extended nanobodies\u00ae","volume":"4","author":"Hoefman","year":"2015","journal-title":"Antibodies"},{"key":"10.1016\/j.xcrm.2026.103094_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.759337","article-title":"Pharmacokinetic engineering of OX40-blocking anticalin proteins using monomeric plasma half-life extension domains","volume":"12","author":"Siegemund","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.xcrm.2026.103094_bib34","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.addr.2012.09.039","article-title":"Fusion protein linkers: Property, design and functionality","volume":"65","author":"Chen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.xcrm.2026.103094_bib35","article-title":"A self-assembled protein platform for plug-and-play customization of multivalent artificial antibodies and antibody-drug conjugates","volume":"64","author":"Chen","year":"2025","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.xcrm.2026.103094_bib36","article-title":"Chemokine-based injectable navigation system for enhancing CAR-T cell therapy against solid tumors","volume":"34","author":"Wan","year":"2024","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.xcrm.2026.103094_bib37","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/nmat4644","article-title":"Biomimetic proteolipid vesicles for targeting inflamed tissues","volume":"15","author":"Molinaro","year":"2016","journal-title":"Nat. Mater."},{"key":"10.1016\/j.xcrm.2026.103094_bib38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/tcrm.2007.3.1.133","article-title":"Adalimumab in the treatment of arthritis","volume":"3","author":"Mease","year":"2007","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.xcrm.2026.103094_bib39","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/rheumatology\/keaa580","article-title":"Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I\/III trial","volume":"60","author":"Westhovens","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.xcrm.2026.103094_bib40","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jim.2007.11.012","article-title":"Lymph node mapping in the mouse","volume":"332","author":"Harrell","year":"2008","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.xcrm.2026.103094_bib41","article-title":"Enhancing adoptive T cell therapy for solid tumor with cell-surface anchored immune checkpoint inhibitor nanogels","volume":"45","author":"Chen","year":"2022","journal-title":"Nanomedicine."},{"key":"10.1016\/j.xcrm.2026.103094_bib42","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nrd4608","article-title":"From sewer to saviour \u2014 targeting the lymphatic system to promote drug exposure and activity","volume":"14","author":"Trevaskis","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.103094_bib43","doi-asserted-by":"crossref","first-page":"18428","DOI":"10.1021\/acsnano.6c05667","article-title":"Predominance of the Noncell-Mediated Migration Mechanism for Large Nanoparticles into Sentinel Lymph Nodes","volume":"20","author":"Wu","year":"2026","journal-title":"ACS Nano"},{"key":"10.1016\/j.xcrm.2026.103094_bib44","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.4049\/jimmunol.1401218","article-title":"Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions","volume":"194","author":"Grevys","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2026.103094_bib45","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1074\/jbc.M109.081828","article-title":"Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding","volume":"285","author":"Andersen","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2026.103094_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah3438","article-title":"Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis","volume":"9","author":"Miner","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.103094_bib47","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41409-024-02237-y","article-title":"Low dose post-transplant cyclophosphamide and sirolimus induce mixed chimerism with CTLA4-Ig or lymphocyte depletion in an MHC-mismatched murine allotransplantation model","volume":"59","author":"Kabore","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.xcrm.2026.103094_bib48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.xcrm.2026.103094_bib49","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nprot.2007.173","article-title":"Collagen-induced arthritis","volume":"2","author":"Brand","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.xcrm.2026.103094_bib50","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41467-023-36468-2","article-title":"Remodeling articular immune homeostasis with an efferocytosis-informed nanoimitator mitigates rheumatoid arthritis in mice","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103094_bib51","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/s41563-024-01865-5","article-title":"A DNA origami device spatially controls CD95 signalling to induce immune tolerance in rheumatoid arthritis","volume":"23","author":"Li","year":"2024","journal-title":"Nat. Mater."},{"key":"10.1016\/j.xcrm.2026.103094_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202108817","article-title":"Immuno-engineered nanodecoys for the multi-target anti-inflammatory treatment of autoimmune diseases","volume":"34","author":"Hou","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.xcrm.2026.103094_bib53","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-2559.2006.02508.x","article-title":"Synovitis score: Discrimination between chronic low-grade and high-grade synovitis","volume":"49","author":"Krenn","year":"2006","journal-title":"Histopathology"},{"key":"10.1016\/j.xcrm.2026.103094_bib54","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2026.103094_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103754","article-title":"Current knowledge of immunosuppression as a risk factor for skin cancer development","volume":"177","author":"Rollan","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.xcrm.2026.103094_bib56","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.ophtha.2023.07.023","article-title":"Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality","volume":"130","author":"Kempen","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xcrm.2026.103094_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202419969","article-title":"Cell Surface-Tethered Nucleic Acid Therapeutics Program Robust and Tumor-Responsive Enhancement of Adoptive Cell Therapy","volume":"37","author":"Gao","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.xcrm.2026.103094_bib58","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/s41551-025-01376-x","article-title":"siRNA conjugate with high albumin affinity and degradation resistance for delivery and treatment of arthritis in mice and guinea pigs","volume":"9","author":"Colazo","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.xcrm.2026.103094_bib59","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/420251","article-title":"The draining lymph node in rheumatoid arthritis: Current concepts and research perspectives","volume":"2015","author":"Benaglio","year":"2015","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.xcrm.2026.103094_bib60","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41584-023-00959-9","article-title":"How does citrullination contribute to RA autoantibody development?","volume":"19","author":"Roudier","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.xcrm.2026.103094_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay1971","article-title":"Targeting inflammatory sites through collagen affinity enhances the therapeutic efficacy of anti-inflammatory antibodies","volume":"5","author":"Katsumata","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xcrm.2026.103094_bib62","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","article-title":"Once-weekly semaglutide in persons with obesity and knee osteoarthritis","volume":"391","author":"Bliddal","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103094_bib63","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus Trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103094_bib64","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index","volume":"26","author":"Junutula","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.103094_bib65","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.103094_bib66","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s44222-023-00082-0","article-title":"Self-assembled lipid-prodrug nanoparticles","volume":"1","author":"Couvreur","year":"2023","journal-title":"Nat. Rev. Bioeng."},{"key":"10.1016\/j.xcrm.2026.103094_bib67","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae--the first FDA-approved nano-drug: Lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.xcrm.2026.103094_bib68","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xcrm.2026.103094_bib69","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq4473","article-title":"Targeting cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.103094_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.dib.2019.104037","article-title":"Determination of the degree of PEGylation of protein bioconjugates using data from proton nuclear magnetic resonance spectroscopy","volume":"25","author":"Zaghmi","year":"2019","journal-title":"Data Brief"},{"key":"10.1016\/j.xcrm.2026.103094_bib71","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nprot.2008.19","article-title":"Protocol for the induction of arthritis in C57BL\/6 mice","volume":"3","author":"Inglis","year":"2008","journal-title":"Nat. Protoc."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126005112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126005112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T15:51:02Z","timestamp":1794930662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126005112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":71,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2666379126005112"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103094","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid-engineered antibody-based therapeutics target inflamed joints and lymph nodes to enhance rheumatoid arthritis treatment","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103094"}}